Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region Advicenne will receive a transfer price and royalties for an amount markedly higher than 50%...

Advicenne provides an update on its activities following its Annual General Meeting Advicenne provides an update on its activities followingits Annual General Meeting Introducing Advicenne 2.0, the Company’s strategy to unlock valuePoised to partner Sibnayal in dRTA in Europe...

Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA) Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA) FDA accepts amended protocol...

Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale (ATRd) Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale...